Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Naidoo M, Levine F, Gillot T, Orunmuyi AT, E Olapade-Olaopa O, Ali T, et al. MicroRNA-1205 Regulation of FRYL in Prostate Cancer. Front Cell Dev Biol. 2021;9:647485.

Leo P, Janowczyk A, Elliott R, Janaki N, Bera K, Shiradkar R, et al. Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. NPJ Precis Oncol. 2021;5(1):35.

Fangazio M, Ladewig E, Gomez K, Garcia-Ibanez L, Kumar R, Teruya-Feldstein J, et al. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2021;118(22).

Manohar J, Abedian S, Martini R, Kulm S, Salvatore M, Ho K, et al. Social and Clinical Determinants of COVID-19 Outcomes: Modeling Real-World Data from a Pandemic Epicenter. medRxiv. 2021.

Vertesich K, Sosa BR, Niu Y, Ji G, Suhardi V, Turajane K, et al. Alendronate enhances osseointegration in a murine implant model. J Orthop Res. 2021;39(4):719-726.

Chan A, Carniello JV, Gao Q, Sigler A, Baik J, Roshal M, et al. Role of Flow Cytometric Immunophenotyping for Classic Hodgkin Lymphoma in Small Biopsy and Cytology Specimens. Arch Pathol Lab Med. 2021.

Karafin MS, Becker JL, Berg M, DeSimone RA, Draper NL, Hudgins J, et al. Heterogeneity in Approaches for Switching From Universal to Patient ABO Type-Specific Blood Components During Massive Hemorrhage: An International Survey and Review of the Literature. Arch Pathol Lab Med. 2021.

Ketas TJ, Chaturbhuj D, Portillo VM, Francomano E, Golden E, Chandrasekhar S, et al. Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathog Immun. 2021;6(1):116-134.

Vega F, Amador C, Chadburn A, Hsi ED, Slack G, L Medeiros J, et al. Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. Mod Pathol. 2021.

Shigeta S, Lui GY, Shaw R, Moser R, Gurley KE, Durenberger G, et al. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Mol Cancer Ther. 2021;20(4):691-703.